Connor Clark & Lunn Investment Management Ltd. Has $909,000 Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB)

Connor Clark & Lunn Investment Management Ltd. raised its position in Nuvation Bio Inc. (NYSE:NUVB) by 9.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 396,736 shares of the company’s stock after purchasing an additional 32,811 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Nuvation Bio were worth $909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in Nuvation Bio in the 3rd quarter valued at $172,000. SG Americas Securities LLC grew its holdings in shares of Nuvation Bio by 125.8% during the 3rd quarter. SG Americas Securities LLC now owns 72,057 shares of the company’s stock worth $165,000 after purchasing an additional 40,141 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Nuvation Bio during the 2nd quarter worth $29,000. Algert Global LLC grew its holdings in shares of Nuvation Bio by 281.0% during the 2nd quarter. Algert Global LLC now owns 426,603 shares of the company’s stock worth $1,246,000 after purchasing an additional 314,635 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC grew its holdings in shares of Nuvation Bio by 252.0% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 76,494 shares of the company’s stock worth $223,000 after purchasing an additional 54,762 shares in the last quarter. 61.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Nuvation Bio

In related news, Director Robert Mashal acquired 100,000 shares of the stock in a transaction dated Tuesday, October 8th. The stock was bought at an average cost of $2.20 per share, for a total transaction of $220,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $220,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.07% of the stock is owned by corporate insiders.

Nuvation Bio Price Performance

NYSE:NUVB opened at $2.89 on Thursday. The firm has a market capitalization of $972.69 million, a PE ratio of -1.33 and a beta of 1.35. Nuvation Bio Inc. has a twelve month low of $1.22 and a twelve month high of $4.16. The stock’s 50-day simple moving average is $2.50 and its 200 day simple moving average is $2.88.

Nuvation Bio (NYSE:NUVB) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $0.73 million during the quarter. On average, analysts anticipate that Nuvation Bio Inc. will post -0.4 EPS for the current fiscal year.

Analyst Ratings Changes

NUVB has been the topic of several analyst reports. Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a report on Thursday, November 7th. HC Wainwright reduced their target price on Nuvation Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Finally, Royal Bank of Canada raised their price objective on Nuvation Bio from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nuvation Bio has an average rating of “Buy” and a consensus target price of $6.60.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.